Mansoura Veterinary Medical Journal
Document Type
Original Article
Keywords
EA-ZnNPs; STZ; Diabetes; Heart; Liver
Abstract
Background:
Biochemical, molecular, and histopathological alterations are the most noticeable clinical and pathological characteristics attributed to diabetes mellitus. An imbalance in these parameters increases the risk of developing complications. Therefore, the main objective of this study was to determine the cardiac and hepatic protective effects of ellagic acid-loaded zinc nanoparticles (EA-ZnNPs) on diabetes, which were evaluated biochemically, molecularly, and histopathologically.
Methods: Four groups of 40 adult male rats were established in this study. The groups were subsequently classified as control, streptozotocin (STZ) diabetic, STZ treated with ellagic acid-loaded zinc nanoparticles (EA-ZnNPs), and STZ treated with insulin. After six weeks of treatment, blood, heart, and liver tissue samples were obtained, and biochemical, molecular, and histopathological examination were performed.
Results:
Treatment with EA-ZnNPs or insulin had significant consequences, as evidenced by the restoration of cardiac and hepatic damage, as well as a substantial reduction in the serum levels of heart and liver-related parameters, such as triglycerides, serum cholesterol, creatine kinase MB isoenzyme (CK-
MB), lactate dehydrogenase (LDH), ALT, AST, cardiac and hepatic malondialdehyde (MDA), glutathione peroxidase (GPx), catalase, and inflammatory indices. Additionally, there were notable histological changes in the hepatic histoarchitecture of diabetic rats treated with EA-ZnNPs.
Conclusion:
EA-ZnNPs could serve to preserve the liver and cardiac tissue in rats with diabetes.
How to Cite This Article
Elsayed, Gehad R. M.; Abdelmagid, Afaf D.; Huseiny, Hatem B.; Fotoh, Ahmed; and Shoker, Faten E.
(2024)
"Impact of ellagic acid loaded zinc nanoparticles on cardiac and hepatic tissue on Type 1 diabetic rats,"
Mansoura Veterinary Medical Journal: Vol. 25:
Iss.
4, Article 6.
DOI: https://doi.org/10.35943/2682-2512.1249
Receive Date
Mar 11, 2024
Accept Date
Sep 4, 2024
Publication Date
2024